Роль рецептора трансформирующего фактора роста бета I Типа в прогрессии люминального подтипа рака молочной железы

Abstract

Identification of additional biomarkers that are able to predict prognosis and treatment response may be very useful to distinguish patients who will benefit from tamoxifen treatment. The aim of the study was to examine the relationship between the protein and receptor gene expression of transforming growth factor β type I (TGF-βRI) and its polymorphism with progression of luminal breast cancer patients treated by adjuvant tamoxifen. Our data suggest that TGF-βRI protein expression level can be a potential molecular marker of tamoxifen resistance in the luminal breast cancer patients.